Aethlon Medical [AEMD] says it has reestablished efforts to advance its Hemopurifier within U.S. government programs that support the development and purchase of treatment countermeasures against bio-terror threats. The Hemopurifier is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Based on previous studies, the company believes the device may be the only broad spectrum countermeasure against viral threats most likely to be weaponized against civilian and military populations. “Revamped government policies expand the opportunity for our Hemopurifier in the United States and improve our potential access to non-dilutive capital resources, which are not capped by the public market value of our organization,” says Jim Joyce, chairman and CEO of Aethlon. “We now plan to update an investigational device exemption already submitted to the Food and Drug Administration, which if approved, would allow us to collect further clinical data that potentially could contribute to other infectious disease and cancer studies we hope to initiate in the United States.” The Hemopurifier is being developed and tested against a range of diseases such as cancer, Hepatitis-C and Human Immunodeficiency Virus in addition to bio-terror and pandemic threats.